A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients

BJU International

Volumn 85, Issue 6, 2000, Pages 676-681

  Okada, H ^a   Kamidono, S ^a   Yoshioka, T ^a   Okuyama, A ^b   Ozono, S ^a   Hirao, Y ^a   Okajima, E ^c   Yamamoto, K ^a   Kishimoto, T ^d   Park, Y ^a   Kurita, T ^e  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c NARA MEDICAL UNIVERSITY   (Japan)

^d OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Benign prostatic hypertrophy; Japanese; Randomized trial; Tamsulosin; Terazosin

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; TAMSULOSIN; TERAZOSIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; HEART PALPITATION; HEART RATE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; RESIDUAL URINE; SCORING SYSTEM; SINGLE BLIND PROCEDURE; SYMPTOM; URINE FLOW RATE; VERTIGO;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; PRAZOSIN; PROSTATIC HYPERPLASIA; SINGLE-BLIND METHOD; SULFONAMIDES;

EID: 0034025727     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2000.00608.x     Document Type: Article

References (24)

1. 1 Tsukamoto T, Masumori N. Epidemiology and natural history of benign prostatic hyperplasia. Int J Urol 1997; 4: 233-46
2. 2 Kaplan SA, Goluboff ET, Olsson CA et al. Effect of demographic factors, urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia. Urology 1995; 45: 398-405
3. 3 Lepor H, Gup DI, Baumann M, Shapiro E. Comparison of alpha-1 adrenoceptors in the prostate adenoma and prostate capsule of men with symptomatic and asymptomatic benign prostatic hyperplasia. Br J Urol 1991; 67: 493-8
4. 4 Shapiro E, Hartanto V, Lepor H. The response to alpha-blockade in benign prostatic hyperplasia is related to the percent area density of prostatic smooth muscle. Prostate 1992; 21: 297-307
5. 5 Kobayashi S, Tang R, Shapiro E, Lepor H. Characterization and localization of prostatic alpha-1 adrenoceptors using radioligand receptor binding on slide-mounted tissue section. J Urol 1993; 150: 2002-26
6. 6 Kunishima Y, Kawabe K, Niijima T et al. A pharmacological study of alpha adrenergic receptor subtypes in smooth muscle of human urinary bladder base and prostatic urethra. J Urol 1985; 134: 396-8
7. 7 Caine M, Perlberg S, Shapiro E. Phenoxybenzamine for benign prostatic obstruction. Urology 1981; 17: 542-6
8. 8 Kirby RS, Coppinger EWC, Corcoran MO et al. Prazosin in the treatment of prostatic obstruction: a placebo-controlled study. Br J Urol 1987; 60: 136-42
9. 9 Jardin A, Bensadoun H, Delauche-Cavallier MC et al. Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 1991; 337: 1457-61
10. 10 Lepor H, Auerbach S, Puras-Baez A et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992; 148: 1467-74
11. 11 Chapple CR, Carter P, Christmas TJ et al. A three-month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 1994; 74: 50-6
12. 12 Kawabe K, Ueno A, Takimoto Y et al. Use of an alpha 1-blocker, YM617, in the treatment of benign prostatic hypertrophy. YM617 Clinical Study Group. J Urol 1990; 144: 908-12
13. 13 Chapple CR. Selective α1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol 1996; 29: 129-44
14. 14 Lee E, Lee C. Clinical comparison of selective and non-selective α1A-adrenoceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol 1997; 80: 606-11
15. 15 Cockett AT, Aso Y, Chatelain C et al. Recommendations of the international consensus committee. In Cockett ATK. Aso Y, Chatelain C et al. eds, The 2nd International Consultation of Benign Prostatic Hyperplasia. Paris: Pitic Salapatiere, 1993: 533-64
16. 16 Homma Y, Kawabe K, Tsukamoto T et al. Estimated criteria for efficacy of treatment in benign prostatic hyperplasia. Int J Urol 1996; 3: 267-73
17. 17 Beduschi M, Beduschi R, Ostering JE. Alpha-blockade therapy for benign prostatic hyperplasia: from a non-selective to a more selective α1A-adrenergic antagonist. Urology 1998; 51: 861-72
18. 18 Ebihara A, Kondo K, Ohashi K et al. Pharmacokinetics and pharmacological properties of terazosin hydrochloride, a new α1 blocker - a single dose study on Japanese healthy subjects. Clin Med Pharmaceut 1987; 3: 667-79
19. 19 Brawer MK, Adams G, Epstein H et al. Terazosin in the treatment of benign prostatic hyperplasia. Arch Fam Med 1993; 2: 929-35
20. 20 Chapple CR, Wyndaele JJ, Nordling J et al. Tamsulosin, the first prostate-selective α1A-adrenoceptor antagonist: a meta-analysis of two randomized, placebo-controlled multicenter studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996; 29: 155-67
21. 21 Lepor H, and the Tamsulosin Investigator Group. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998; 51: 892-900
22. 22 Okada H, Kawaida N, Ogawa T et al. Tamsulosin and chlormadinone for the treatment of benign prostatic hyperplasia. Scan J Urol Nephrol 1996; 30: 379-85
23. 23 Kumamoto Y, Tsukamoto T, Yachiku S et al. Clinical evaluation of terazosin hydrochloride on urinary obstruction caused by benign prostatic hypertrophy (II): Double-blind comparative study compared with placebo. Hinyoukigeka 1992; 5: 823-40
24. 24 Chapple CR. Medical therapy and quality of life. Eur Urol 1998; 34: 16-7